Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999

Clinical Infectious Diseases

Volumn 31, Issue 6, 2000, Pages 1482-1487

  Thiébaut, Rodolphe ^a   Daucourt, Valentin ^a   Mercié, Patrick ^a   Ekouévi, Didier K ^a   Malvy, Denis ^a   Morlat, Philippe ^a   Dupon, Michel ^a   Neau, Didier ^a   Farbos, Sophie ^b   Marimoutou, Catherine ^a   Dabis, François ^a,c  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b Centre hospitalier de Bayonne   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DRUG COMBINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; MALE; METABOLIC DISORDER; MIDDLE AGED; PREVALENCE; RISK FACTOR;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LIPODYSTROPHY; MALE; METABOLIC DISEASES; MIDDLE AGED; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS;

EID: 18044376212     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/317477     Document Type: Article

References (24)

1. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74:1045-52.
2. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
3. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998;12: F37-9.
4. De Luca A, Murri R, Damiano F, Ammassari A, Antinori A. "Buffalo hump" in HIV-1 infection. Lancet 1998;352:320.
5. Miller KD, Jones E, Yanovski JA. Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998;351:871-5.
6. Miller KK, Daly PA, Sentochnik D, et al. Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients. Clin Infect Dis 1998;27:68-72.
7. Perry RC, Cushing HE, Deeg MA, Prince MJ. Ritonavir, triglycerides, and pancreatitis. Clin Infect Dis 1999;28:161-2.
8. Behrens G, Schmidt H, Meyer D, Stoll M, Schmidt RE. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998;351:1958.
9. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998;351:1328.
10. Gallet B, Pulik M, Genet P, Chedin P, Hiltgen M. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998;351:1958-9.
11. SoRelle R. Vascular and lipid syndromes in selected HIV-infected patients. Circulation 1998;98:829-30.
12. Vittecoq D, Escaut L, Monsuez JJ. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998;351:1959.
13. Dong KL, Bausserman LL, Flynn MM, et al. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr 1999;21:107-13.
14. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999;13:465-71.
15. Martinez E, Gatell J. Metabolic abnormalities and use of HIV-1 protease inhibitors. Lancet 1998;352:821-2.
16. Wurtz R. Abnormal fat distribution and use of protease inhibitors. Lancet 1998;351:1735-6.
17. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet 1998;351:867-70.
18. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13:1659-67.
19. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;351:1881-3.
20. Ho TT, Chan KC, Wong KH, Lee SS. Abnormal fat distribution and use of protease inhibitors. Lancet 1998;351:1736-7.
21. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999;354:1112-5.
22. Marimoutou C, Chene G, Dabis F, Lacoste D, Salamon R. Human immunodeficiency virus infection and AIDS in Aquitaine. 10 years' experience of a hospital information system, 1985-1995. Le Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA) [in French]. Presse Med 1997;26:703-10.
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
24. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41(RR-17):1-19.